Una actualización | 16 SEP 13

Síndrome de Tourette

Es un trastorno con tics motores y vocales que con frecuencia se asocia a alteraciones de la conducta. Las estrategias terapéuticas son la psicoeducación, conductuales y ciertos medicamentos.
Autor/a: Dres. Cavanna AE, Seri S BMJ 2013;347:f4964
INDICE:  1.  | 2. Referencias
Referencias

1 Stern JS, Burza S, Robertson MM. Gilles de la Tourette’s syndrome and its impact in the UK. Postgrad Med J 2005; 81:12-9.
2 Gilles de la Tourette G. Etude sur une affection nerveuse caracterisée par de l’incoordination motrice accompagnée d’écholalie et de copralalie. Arch Neurol (Paris) 1885; 9:19-42;158-200.
3 Robertson MM, Eapen V, Cavanna AE. The international prevalence, epidemiology and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res 2009; 67:475-83.
4 Scharf JM, Miller LL, Mathews CA, Ben-Schlomo Y. Longitudinal study of parents and children cohort. J Am Acad Child Adolesc Psychiatry 2012; 51:192-201.
5 Hassan N, Cavanna AE. The prognosis of Tourette syndrome: Implications for clinical practice. Funct Neurol 2012; 27:23-7.
6 Cavanna AE, Rickards H. The psychopathological spectrum of Gilles de la Tourette syndrome. Neurosci Biobehav Rev 2013; 37:1008-15.
7 Crossley E, Cavanna AE. Sensory phenomena: clinical correlates and impact on quality of life in adult patients with Tourette syndrome. Psychiatry Res [forthcoming].
8 Eddy CM, Cavanna AE. Altered social cognition in Tourette syndrome: nature and implications. Behav Neurol 2013; 27:15-22.
9 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. APA, 2013.
10 Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P. An international perspective on Tourette syndrome: selected findings from 3500 individuals in 22 countries. Dev Med Child Neurol 2000; 42:436-47.
11 Cavanna AE, Critchley HD, Orth M, Stern JS, Young M-B, Robertson MM. Dissecting the Gilles de la Tourette spectrum: a factor analytic study on 639 patients. J Neurol Neurosurg Psychiatry 2011; 82:1320-3.
12 Khalifa N, Von Knorring A-L. Tourette syndrome and other tic disorders in a total population of children: clinical assessment and background. Acta Paediatr 2005; 94:1608-14.
13 Worbe Y, Mallet L, Golmard JL, Béhar C, Durif F, Jalenques I, et al. Repetitive behaviours in patients with Gilles de la Tourette syndrome: tics, compulsions, or both? PLoS One 2010; 5:e12959.
14 Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009; 48:884-93.
15 Robertson MM. Mood disorders and Gilles de la Tourette’s syndrome: an update on prevalence, etiology, comorbidity, clinical associations, and implications. J Psychosom Res 2006; 61:349-58.
16 Wright A, Rickards H, Cavanna AE. Impulse control disorders in Gilles de la Tourette syndrome. J Neuropsychiatry Clin Neurosci 2012; 24:16-27.
17 Cavanna AE, Robertson MM, Critchley HD. Schizotypal personality traits in Gilles de la Tourette syndrome. Acta Neurol Scand 2007; 116:385-91.
18 Jankovic J, Kwak C, Frankoff R. Tourette syndrome and the law. J Neuropsychiatry Clin Neurosci 2006; 18:86-95.
19 Eddy CM, Rizzo R, Gulisano M, Agodi A, Barchitta M, Calì P, et al. Quality of life in young people with Tourette syndrome: a controlled study. J Neurol 2011; 258:291-301.
20 Cavanna AE, Schrag A, Morley D, Orth M, Robertson MM, Joyce E, et al. The Gilles de la Tourette syndrome-quality of life scale (GTS-QOL): development and validation.
Neurology 2008; 71:1410-6.
21 Felling RJ, Singer HS. Neurobiology of Tourette syndrome: current status and need for further investigation. J Neurosci 2011; 31:12387-95.
22 Ali F, Morrison KE, Cavanna AE. The complex genetics of Gilles de la Tourette syndrome: implications for clinical practice. Neuropsychiatry 2013; 3:321-30.
23 Madhusudan N, Cavanna AE. The role of immune dysfunction in the development of tics and susceptibility to infections in Tourette syndrome: a systematic review. Basal Ganglia 2013; 3:77-84.
24 Cavanna AE, Rickards H, Worrall R, Hoekstra PJ, Plessen KJ, Roessner V. From ipse dixit to evidence-based guidelines: on the optimal management of Tourette syndrome. Eur J Paediatr Neurol 2012; 16:310-1.
25 Cath DC, Hedderly T, Ludolph AG, Stern JS, Murphy T, Hartmann A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment. Eur Child Adolesc Psychiatry 2011; 20:155-71.
26 Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 2011; 20:173-96.
27 Verdellen C, van de Griendt J, Hartmann A, Murphy T; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry 2011; 20:197-207.
28 Muller-Vahl KR, Cath DC, Cavanna AE, Dehning S, Porta M, Robertson MM, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. Eur Child Adolesc Psychiatry 2011; 20:209-17.
29 Frank M, Cavanna AE. Behavioural treatments for Tourette syndrome: an evidence-based review. Behav Neurol 2013; 27:105-17.
30 Piacentini J, Woods DW, Scahill L, Wilhelm S, Peterson AL, Chang S, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA 2010; 303:1929-37.
31 Wilhelm S, Peterson AL, Piacentini J, Woods DW, Deckersbach T, Sukhodolsky DG, et al. Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry 2012; 69:795-803.
32 Waldon K, Hill S, Termine C, Balottin U, Cavanna AE. Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behav Neurol 2013; 26:265-73.
33 Thomas R, Cavanna AE. The pharmacology of Tourette syndrome. J Neural Transm 2013; 120:689-94.
34 Vandewalle V, van der Linden C, Groenewegen HJ, Caemaert J. Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet 1999; 353:724.
35 Piedad JCP, Rickards HE, Cavanna AE. What patients with Gilles de la Tourette syndrome should be treated with deep brain stimulation and what is the best target? Neurosurgery 2012; 71:173-92.
 

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021